NCT06613841View on ClinicalTrials.gov

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

December 31, 2026

Conditions
GlioblastomaRecurrent GlioblastomaGlioblastoma Multiforme of Brain
Interventions
DRUG

Fluciclovine F18

To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.

Trial Locations (2)

19104

RECRUITING

Hospital of the University of Pennsylvania, Philadelphia

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER